Table 2.
Comparison of progression-free survival in each subgroup.
| RECIST v1.1 | mRECIST | |||
|---|---|---|---|---|
| 6 weeks | Best response | 6 weeks | Best response | |
| CR, n (%) | 0 (0.0) | 3 (2.9) | 2 (1.9) | 9 (8.7) |
| PR, n (%) | 9 (8.7) | 17 (16.3) | 18 (17.3) | 20 (19.2) |
| SD, n (%) | 74 (71.2) | 63 (60.6) | 61 (58.7) | 51 (49.0) |
| PD, n (%) | 18 (17.3) | 21 (20.2) | 12 (12.5) | 16 (15.4) |
| NE, n (%) | 3 (2.9) | 0 (0.0) | 10 (9.6) | 8 (7.7) |
| ORR, n (%) | 9 (8.7) | 20 (19.2) | 20 (19.2) | 29 (27.9) |
| DCR, n (%) | 83 (79.8) | 83 (79.8) | 81 (77.9) | 80 (76.9) |
Abbreviations: CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, NE: not evaluable, ORR: objective response rate, DCR: disease control rate.